Korean
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Polski Merkuriusz Lekarski 2010-Dec

[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
링크가 클립 보드에 저장됩니다.
Małgorzata Chilimoniuk
Ewa Olszewska
Tomasz Maksimowicz

키워드

요약

The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies. Results of treatment for locally advanced squamous cell head and neck cancer with surgery and/or radiotherapy are still unsatisfactory. During last decade concomitant chemoradiotherapy became a new standard in this group of patients. The treatment method is charged of high toxicity and real therapeutic advantages are obtained by limited number of patients. Intensive clinical investigations on novel therapeutic strategies are in progress. One of them is the combination of induction chemotherapy with taxan (TPF) and concomitant chemoradiotherapy join with cisplatin. The aim of the study was to estimate the treatment tolerance and early term results with combination of induction chemotherapy with TPF and concomitant chemoradiotherapy join with cisplatin in patients with locally advanced, squamous cell carcinoma of head and neck.

METHODS

Patients with locally advanced oropharyngeal and larynx cancer treated in the Institute of Oncology in Bialystok at the Department of Radiotherapy II from latter half of 2009 year were included in the study. The treatment protocol consisted of 3 courses of induction chemotherapy TPF (Taxotere 75 mg/m2, DDP 100 mg/m2, 5-Fluorouracyl 1000 mg/m2 every 3 weeks) and conventionally fractionated radiotherapy (Df=2 Gy, 5 x weekly) to total dose of 66-72 Gy and for neck cervical lymph nodes up to 60-66 Gy with concomitant of cisplatin 100 mg/m2 every 3 weeks. Early reactions were estimated according to EORTC/RTOG scales, and chemotherapy tolerance was evaluated according to the CTC scale. Twelve patients with homogenous criteria were included in the study.

RESULTS

The treatment tolerance was acceptable. However several adverse reactions were present. The main adverse effect was the extensive mucosal reaction. Neutropenia and anemia were also observed in most of the patients. Some patients complained of diarrhea, vomiting and nausea in mild or moderate intensity which were persisted temporarily.

CONCLUSIONS

Induction chemotherapy TPF and concomitant radiochemotherapy with cisplatin in patients with locally advanced head and neck cancer in III-IV clinical stages came out as the treatment of high efficacy.

페이스 북
페이지에 가입하세요

과학이 뒷받침하는 가장 완벽한 약초 데이터베이스

  • 55 개 언어로 작동
  • 과학이 뒷받침하는 약초 치료제
  • 이미지로 허브 인식
  • 인터랙티브 GPS지도-위치에 허브 태그 지정 (출시 예정)
  • 검색과 관련된 과학 출판물 읽기
  • 효과로 약초 검색
  • 관심사를 정리하고 뉴스 연구, 임상 실험 및 특허를 통해 최신 정보를 확인하세요.

증상이나 질병을 입력하고 도움이 될 수있는 약초에 대해 읽고 약초를 입력하고 사용되는 질병과 증상을 확인합니다.
* 모든 정보는 발표 된 과학 연구를 기반으로합니다.

Google Play badgeApp Store badge